|
1.
|
|
11 p, 1.4 MB |
Prognostic gene expression signature for high-grade serous ovarian cancer
/
Millstein, Joshua (University of Southern California) ;
Budden, Timothy (The University of Manchester) ;
Goode, Ellen L. (Mayo Clinic) ;
Anglesio, Michael (University of British Columbia) ;
Talhouk, Aline (University of British Columbia) ;
Intermaggio, Maria Paola (University of NSW Sydney) ;
Leong, Hueisan (Peter MacCallum Cancer Center) ;
Chen, Stephanie S. (Cedars-Sinai Medical Center) ;
Elatre, Wafaa A. (University of Southern California) ;
Gilks, Cyril Blake (University of British Columbia) ;
Nazeran, Tayyebeh M. (University of British Columbia) ;
Volchek, Mila (Royal Women's Hospital) ;
Bentley, Rex C. (Duke University Hospital) ;
Wang, Chen (Mayo Clinic) ;
Chiu, Derek S. (University of British Columbia) ;
Kommoss, Stefan (Tuebingen University Hospital) ;
Leung, Samuel C. Y. (University of British Columbia) ;
Senz, Janine (University of British Columbia) ;
Lum, Amy (University of British Columbia) ;
Chow, Veronica (University of British Columbia) ;
Sudderuddin, Hanwei (University of British Columbia) ;
Mackenzie, Robertson (University of British Columbia) ;
George, Joshy (The Jackson Laboratory for Genomic Medicine) ;
Fereday, Sian (University of Melbourne) ;
Hendley, Joy (University of Melbourne) ;
Traficante, Nadia (University of Melbourne) ;
Steed, Helen (Royal Alexandra Hospital) ;
Koziak, Jennifer M. (Alberta Health Services-Cancer Care) ;
Köbel, Martin (Foothills Medical Center) ;
McNeish, Iain (University of Glasgow) ;
Goranova, Teodora Evgenieva (University of Cambridge) ;
Ennis, Darren P. (University of Glasgow) ;
Macintyre, Geoff (University of Cambridge) ;
Silva De Silva, D. (University of Cambridge) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
García Donas, J. (HM Hospitales D Centro Integral Oncológico HM Clara Campal) ;
Hernando, Susana (Hospital Universitario Funcacion Alcorcon) ;
Rodriguez, Gustavo C. (University of Chicago) ;
Cushing-Haugen, Kara L. (Fred Hutchinson Cancer Research Center) ;
Harris, Holly Ruth (University of Washington) ;
Greene, Casey S. (University of Pennsylvania) ;
Zelaya, René A. (Geisel School of Medicine at Dartmouth) ;
Behrens, Sabine (German Cancer Research Center (DKFZ)) ;
Fortner, Renée T. (German Cancer Research Center (DKFZ)) ;
Sinn, Hans-Peter (Heidelberg University Hospital (Alemanya)) ;
Herpel, Esther (University Hospital and German Cancer Research Center) ;
Lester, Jenny (Cedars-Sinai Medical Center) ;
Lubinski, Jan (Pomeranian Medical University) ;
Oszurek, Oleg (Pomeranian Medical University) ;
Tołoczko, Aleksandra D. (Pomeranian Medical University) ;
Cybulski, Cezary (Pomeranian Medical University) ;
Menkiszak, Janusz Leszek (Pomeranian Medical University) ;
Pearce, Celeste Leigh (University of Southern California Norris Comprehensive Cancer Center) ;
Pike, Malcolm C. (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Tseng, Chiuchen Cheng (University of Southern California) ;
Alsop, Jennifer (University of Cambridge) ;
Rhenius, Valerie (University of Cambridge) ;
Song, Hongan (University of Cambridge) ;
Jimenez-Liñan, Mercedes (Addenbrooke's Hospital NHS Trust) ;
Piskorz, Anna M. (University of Cambridge) ;
Gentry-Maharaj, Aleksandra (University College London) ;
Karpinskyj, Chloe (University College London) ;
Widschwendter, M. (University College London) ;
Singh, Naveena K. (Barts Health National Health Service Trust) ;
Kennedy, Catherine J. (Westmead Hospital) ;
Harnett, Paul R. (University of Sidney) ;
Gao, Bo (Westmead Hospital) ;
Johnatty, Sharon E. (QIMR Berghofer Medical Research Institute (Brisbane, Austràlia)) ;
Sayer, Robyn A. (Westmead Hospital) ;
Boros, Jessica (Westmead Hospital) ;
Winham, Stacey J. (Mayo Clinic) ;
Keeney, Gary L. (Mayo Clinic) ;
Kaufmann, Scott H. (Mayo Clinic) ;
Larson, Melissa C. (Mayo Clinic) ;
Luk, Hugh W. (University of Hawaii Cancer Center) ;
Hernandez, Brenda Y. (University of Hawaii Cancer Center) ;
Thompson, Pamela J. (Cedars-Sinai Medical Center) ;
Wilkens, Lynne Ross (University of Hawaii Cancer Center) ;
Carney, Michael E. (University of Hawaii) ;
Trabert, Britton (National Cancer Institute) ;
Lissowska, Jolanta (M Sklodowska Curie National Research Institute of Oncology) ;
Brinton, Louise Annette (National Cancer Institute) ;
Sherman, Mark E. (Mayo Clinic College of Medicine) ;
Bodelón, Clara (National Cancer Institute) ;
Hinsley, Samantha (University of Glasgow) ;
Lewsley, Liz Anne (University of Glasgow) ;
Glasspool, Rosalind M. (University of Glasgow) ;
Banerjee, Susana (The Royal Marsden NHS Foundation Trust and Institute of Cancer Research) ;
Stronach, Euan A. (Imperial College London) ;
Haluska, Paul J. (Mayo Clinic) ;
Ray-Coquard, Isabelle Laure (Centre Leon Berard and University Claude Bernard Lyon 1) ;
Mahner, Sven (LMU Munich) ;
Winterhoff, Boris J. N. (University of Minnesota) ;
Slamon, Dennis J. (University of California at Los Angeles) ;
Levine, Douglas A. (NYU Langone Medical Center) ;
Kelemen, Linda E. (Medical University of South Carolina) ;
Benitez, Javier J. (Centro Nacional de Investigaciones Oncológicas) ;
Chang-Claude, J. (University Medical Center Hamburg-Eppendorf) ;
Gronwald, Jacek (Pomeranian Medical University) ;
Wu, Anna H. (University of Southern California) ;
Menon, Usha (MRC University College London) ;
Goodman, Marc T. (Cedars-Sinai Medical Center) ;
Schildkraut, Joellen M. (Emory University) ;
Wentzensen, Nicolas A. (National Cancer Institute) ;
Brown, Robert (Imperial College London) ;
Berchuck, Andrew (Duke University Hospital) ;
Gayther, Simon A. (Cedars-Sinai Medical Center) ;
García, M. J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Henderson, Michelle J. (University of NSW Sydney) ;
Rossing, Mary Anne (University of Washington) ;
Beeghly-Fadiel, Alicia (Vanderbilt University School of Medicine) ;
Fasching, Peter Andreas (Friedrich-Alexander-University Erlangen-Nuremberg) ;
Orsulic, Sandra (Cedars-Sinai Medical Center) ;
Karlan, Beth Y. (Cedars-Sinai Medical Center) ;
Konecny, Gottfried Ewald (University of California at Los Angeles) ;
Huntsman, David G. (BC Cancer Research Centre) ;
Brenton, James D. (University of Cambridge) ;
Doherty, Jennifer Anne (University of Utah) ;
Pharoah, Paul D. P. (University of Cambridge) ;
Ramus, Susan (University of NSW Sydney) ;
Universitat Autònoma de Barcelona
Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. [...]
2020 -  10.1016/j.annonc.2020.05.019
Annals of oncology, Vol. 31 Núm. 9 (01 2020) , p. 1240-1250
|
|
|
2.
|
|
10 p, 809.5 KB |
The MUK five protocol : a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
/
Brown, Sarah (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Hinsley, Samantha (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Ballesteros Silva, Mónica Patricia (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Bourne, Sue (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
McGarry, Paul (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Sherratt, Debbie (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Flanagan, Louise (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Gregory, Walter (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Cavenagh, Jamie (St Bartholomew's Hospital (Regne Unit)) ;
Owen, Roger (HMDS Laboratory, St James's University Hospital, Leeds, UK) ;
Williams, Cathy (Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK) ;
Kaiser, Martin (The Institute of Cancer Research, Sutton, UK) ;
Low, Eric (Myeloma UK, Edinburgh, UK) ;
Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit))
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40-50 per million i. e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. [...]
2016 - 10.1186/s12878-016-0053-9
BMC Hematology, Vol. 16 (may 2016)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
